157 related articles for article (PubMed ID: 17692534)
21. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
22. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
Xu P; Andreasen PA; Huang M
Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
[TBL] [Abstract][Full Text] [Related]
23. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for the activity of pp60(c-src) protein tyrosine kinase inhibitors.
Prabhu NV; Siddiqui SA; McMurray JS; Pettitt BM
Biopolymers; 2001 Sep; 59(3):167-79. PubMed ID: 11391566
[TBL] [Abstract][Full Text] [Related]
25. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
[TBL] [Abstract][Full Text] [Related]
27. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
[TBL] [Abstract][Full Text] [Related]
28. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Barbault F; Maurel F
J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
[TBL] [Abstract][Full Text] [Related]
29. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
30. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
31. Cyclic peptide analysis of the biologically active loop region in the laminin alpha3 chain LG4 module demonstrates the importance of peptide conformation on biological activity.
Kato-Takagaki K; Suzuki N; Yokoyama F; Takaki S; Umezawa K; Higo J; Mochizuki M; Kikkawa Y; Oishi S; Utani A; Nomizu M
Biochemistry; 2007 Feb; 46(7):1952-60. PubMed ID: 17261031
[TBL] [Abstract][Full Text] [Related]
32. Mapping the putative binding site for uPA protein in Esophageal Cancer-Related Gene 2 by heteronuclear NMR method.
Geng Y; Feng Y; Xie T; Dai Y; Wang J; Lu SH
Arch Biochem Biophys; 2008 Nov; 479(2):153-7. PubMed ID: 18824154
[TBL] [Abstract][Full Text] [Related]
33. Crystal structures of Escherichia coli gamma-glutamyltranspeptidase in complex with azaserine and acivicin: novel mechanistic implication for inhibition by glutamine antagonists.
Wada K; Hiratake J; Irie M; Okada T; Yamada C; Kumagai H; Suzuki H; Fukuyama K
J Mol Biol; 2008 Jul; 380(2):361-72. PubMed ID: 18555071
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
[TBL] [Abstract][Full Text] [Related]
35. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel inhibitor of urokinase-type plasminogen activator.
Zhu M; Gokhale VM; Szabo L; Munoz RM; Baek H; Bashyam S; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2007 Apr; 6(4):1348-56. PubMed ID: 17431113
[TBL] [Abstract][Full Text] [Related]
37. Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
Zeslawska E; Schweinitz A; Karcher A; Sondermann P; Sperl S; Stürzebecher J; Jacob U
J Mol Biol; 2000 Aug; 301(2):465-75. PubMed ID: 10926521
[TBL] [Abstract][Full Text] [Related]
38. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
[TBL] [Abstract][Full Text] [Related]
39. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
[TBL] [Abstract][Full Text] [Related]
40. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]